Dopamine Agonists
- Summary
- Researchers at Purdue University have developed new molecules that fully and selectively activate the dopamine D1 receptor. The compounds derived are useful for treating patients having a dopamine-related dysfunction of the central nervous system (CNS) as well as conditions in which peripheral dopamine receptors are involved. They are expected to be effective against Parkinson's disease, improving cognition, memory, attention deficit hyperactivity disorder, and related developmental disorders.
- Technology Benefits
- Lead compound is 50 times more selective for D1 receptors than for D2L receptorsEquipotent, but more selective than other D1 agonists Potentially effective treatment for advanced Parkinson's disease and other CNS disordersOrally bioavailable in animal models
- Technology Application
- Medical/HealthcarePharmaceuticalsDrug Development
- Detailed Technology Description
- David NicholsPurdue Medicinal Chemistry and Molecular Pharmacology
- Countries
- United States
- Application No.
- 8,318,938
- *Abstract
-
- *Background
- Dopamine is a neurotransmitter in the central nervous system that has been implicated in numerous neurological disorders. For example, excess stimulation of dopamine may be linked to schizophrenia, whereas either excessive or insufficient functional dopaminergic activity may cause hypertension, narcolepsy, and other disorders including Parkinson's disease. The D1 receptor is a dopamine receptor subtype that may be a viable therapeutic target for dopamine-related pathologies. Accordingly, researchers have directed their efforts to design ligands that are selective D1 receptor agonists.
- *IP Issue Date
- Nov 27, 2012
- *IP Type
- Utility
- *Stage of Development
- Proof of Concept
- *Web Links
- Purdue Office of Technology CommercializationPurdueInnovation and EntrepreneurshipDavid NicholsPurdue Medicinal Chemistry and Molecular Pharmacology
- Country/Region
- USA
For more information, please click Here
